$IONS News Article - Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session https://marketwirenews.com/news-releases/ioni...79798.html
(0)
(0)
Ionis Pharmaceuticals, Inc. (IONS) Stock Research Links